By Brad Sorensen, CFA
READ THE FULL TELO RESEARCH REPORT
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”
The company continues to learn about the potential uses for Telomir-1 and just announced that it successfully captured and stabilized both Silver(I) (Ag⁺) and the highly reactive Silver(II) (Ag²⁺) in a biologically compatible form. As you probably know, silver has long been used in medicine due to its antimicrobial effects. Silver(II) (Ag²⁺) is a rare oxidation state of silver, as silver typically exists in the +1 oxidation state Silver(I) (Ag⁺). While Silver(I) compounds have demonstrated strong antibacterial activity, Silver(II) offers enhanced healing potential due to its greater oxidative capacity, broader bactericidal activity, and potential role in tissue regeneration. This is a significant development as some methods have briefly stabilized Silver(II) in lab conditions, those approaches are not viable for biological applications.
The ability to harness the abilities of Silver(II) has an enormous potential impact, including:
- Increased Oxidizing Power – Ag²⁺ is a stronger oxidizing agent than Ag⁺, which could make it more effective at disrupting bacterial cell membranes, proteins, and DNA, potentially leading to enhanced antimicrobial activity.
- Broader Antimicrobial Spectrum – Due to its higher oxidation state, Silver(II) could potentially be more effective against antibiotic-resistant bacteria, fungi, and viruses, providing a more comprehensive antimicrobial solution.
- Lower Required Dosage – Stronger reactivity might allow for lower doses of Ag²⁺ to achieve the same or better antimicrobial effects compared to Ag⁺, reducing toxicity concerns and minimizing environmental impact.
- Potential for Catalytic Action – Unlike Ag⁺, which acts as a static antimicrobial agent, Ag²⁺ might participate in redox cycling, continuously regenerating its active form and prolonging its effectiveness.
- Greater Biofilm Disruption – Silver resistance is partly due to biofilm formation. The stronger oxidative properties of Ag²⁺ might enhance its ability to penetrate and disrupt bacterial biofilms more effectively than Ag⁺.
While at the beginning stages of discovery, this development has a large economic potential, with the antimicrobial coatings market expected to grow to almost $34 billion by 2031 according to Verified Market Research. And according to the company’s Chief Scientific Advisor, Dr. Itzchak Angel, “The ability to stabilize Silver(II) has been considered nearly impossible due to its extreme reactivity and rapid degradation. What we have achieved with Telomir-1 represents a significant leap forward in material science and medical chemistry. By stabilizing Silver(II) in a stable, biologically compatible form, we may have unlocked the potential for a new class of therapeutics that could revolutionize topical antimicrobial treatments, wound healing, and infection control. This is more than just a scientific breakthrough—it is the first step toward potentially reshaping how silver-based medicine is used in modern healthcare.”
This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions.
It’s this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the company that develops it. We urge investors who have a higher risk tolerance to take a look at TELO and consider investing in a company at an early stage that has a large potential upside, with a low float and positive news flow likely to continue in the near future, providing potential fuel to the stock.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
